Skip to main content

Withdrawn Drugs


These is much ongoing work within the drug discovery and toxicology communities to better understand the safety aspects of approved drugs and clinical candidate compounds, and for this reason there is clear interest in why some drugs have been approved but then subsequently withdrawn from the market. This post describes the information for withdrawn drugs that is currently available in ChEMBL. 

Within ChEMBL (release 24) there are 192 drugs that have been annotated as approved but then subsequently withdrawn from the market for one or more reasons.  For each of these drugs, the year of withdrawal, region of withdrawal and reason for withdrawal (‘withdrawn_reason’) have been available since release 22 of ChEMBL (see ftp://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_22/archived/chembl_22_release_notes.txt), while the classification of the reason for withdrawal (‘withdrawn_class’)  is a new feature for ChEMBL (release 24).  The withdrawn information is available for relevant drugs on the Compound Report Card of the web interface, or within the molecule_dictionary sql table. 

For example Rosiglitazone, an anti-diabetes medicine, was withdrawn from the EU in 2011 due to the increased risk of ischaemic heart disease (http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp ). Note that Rosiglitazone has been withdrawn from the EU market, but is still available within other regions of the world and hence the Compound Report Card shows that the drug is ‘approved’ (see information within the top of the Compound Report Card - https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL121), while the detail about the region of withdrawal shows that it has been withdrawn from the EU (further down the Compound Report Card). ‘Cardiotoxicity’ is annotated as the withdrawn_class for Rosiglitazone.



Using the withdrawn classification (‘withdrawn_class’), similar withdrawn drugs can be grouped together. For example, if you are interested in approved drugs that have been withdrawn for ‘hepatoxicity’, ‘cardiotoxicity’, ‘neurotoxicity’ etc then you can now easily group drugs withdrawn for similar reasons. Therefore the pie chart displayed below shows 45 drugs that have been withdrawn for hepatotoxicity reasons. 

Of the annotated classes of withdrawn drugs, 37 drugs have more than one reason for withdrawal from the markets (and therefore are assigned more than one class of withdrawn reason on the pie chart); 9 of the withdrawn drugs have not been assigned a withdrawn_class because they have a non-specific reason (e.g. 'Multi-Organ Toxicities') that cannot be given a withdrawn_class without further investigation of the underlying literature; and 44 of the withdrawn drugs do not currently have a reason described in ChEMBL. 

Further work is planned to annotate additional withdrawn drug information. 


This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116030. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.



Comments

Popular posts from this blog

ChEMBL & SureChEMBL anniversary symposium

  In 2024 we celebrate the 15th anniversary of the first public release of the ChEMBL database as well as the 10th anniversary of SureChEMBL. To recognise this important landmark we are organising a two-day symposium to celebrate the work achieved by ChEMBL and SureChEMBL, and look forward to its future.   Save the date for the ChEMBL 15 Year Symposium October 1-2, 2024     Day one will consist of four workshops, a basic ChEMBL drug design workshop; an advanced ChEMBL workshop (EUbOPEN community workshop); a ChEMBL data deposition workshop; and a SureChEMBL workshop. Day two will consist of a series of talks from invited speakers, a few poster flash talks, a local nature walk, as well as celebratory cake. During the breaks, the poster session will be a great opportunity to catch up with other users and collaborators of the ChEMBL resources and chat to colleagues, co-workers and others to find out more about how the database is being used. Lunch and refreshments will be pro

Join the ChEMBL Team!

Come and join us - we are recruiting for a Chemical Biology Team Leader! This is an exciting opportunity to lead the  Chemical Biology resources, based at the Wellcome Genome Campus in Hinxton near Cambridge, UK.  The chemical biology team   at EMBL-EBI delivers world-leading databases and resources to the scientific community. Our flagship resource, ChEMBL ,  is a database of high-quality quantitative small-molecule bioactivity data curated from the scientific literature and direct data depositions. SureChEMBL   is a complementary patent resource containing chemical structures and biology/drug discovery annotations extracted daily from patents. UniChem   links chemical structures across databases.  ChEBI is a database of small molecules relevant to biology. Closing Date: 19th July 2024 More details here

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

Legacy SureChEMBL retirement

Dear SureChEMBL users, About six months ago, we introduced the new version of SureChEMBL. It brought significant improvements in terms of performance and stability, and it also allows us to implement new functionalities. After the survey at the beginning of the year, we prioritised what should be delivered first. You should see the materialisation of our work in the coming months. As originally announced when the new SureChEMBL was introduced, the plan was to shut down the old system permanently to focus all our resources on the new SureChEMBL. This time has come, so expect www.surechembl-legacy.org to be unreachable in the coming days with no turning back! Consequently, and in parallel, the new SureChEMBL will lose its Beta status, and we will stop referring to it as the new version. This does not mean we are reducing our efforts to improve our system; on the contrary, this removes a distraction! If you have any feedback, you can contact us directly at surechembl-help@ebi.ac.uk . We